Journal of Endocrinological Investigation

, Volume 33, Issue 6, pp 436–436 | Cite as

Sorafenib and thyrotoxicosis

  • D. Barbaro
Letter to the Editor


Renal Cell Carcinoma Hypothyroidism Clin Oncol Sorafenib Sunitinib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors — a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009, 10: 470–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009, 6: 219–28.PubMedCrossRefGoogle Scholar
  3. 3.
    Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 2008, 69: 669–72.CrossRefGoogle Scholar
  4. 4.
    Miyake H, Kurahashi T, Yamanaka K, et al. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation. Urol Oncol 2009, Nov 13 [Epub ahead of print]; doi: 10.1016/j.urolonc.2009.08.011.Google Scholar
  5. 5.
    Tamaskar I, Bukowski R, Elson P, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Onc 2008, 19: 265–8.CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2010

Authors and Affiliations

  • D. Barbaro
    • 1
  1. 1.Section of Endocrinology and DiabetologySpedali RiunitiLivornoItaly

Personalised recommendations